CD33 and acute myeloid leukemia: Using this technique, a CD33-targeting CAR-NK with different transmembrane and signaling domains (CD4/4-1BB+CD3ζ and NKG2D/2B4+CD3ζ) was generated, and seemed to show enhanced anti-AML activity in primary NK cells [54].